@article{3100829,
    title = "Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantation",
    author = "Tsirigotis, P. and Danylesko, I. and Gkirkas, K. and Shem-Tov, N. and Yerushalmi, R. and Stamouli, M. and Avigdor, A. and Spyridonidis, A. and Gauthier, J. and Goldstein, G. and Apostolidis, J. and Mohty, M. and Shimoni, A. and Nagler, A.",
    journal = "Bone marrow transplantation. Supplement (Basingstoke)",
    year = "2016",
    volume = "51",
    number = "10",
    pages = "1313-1317",
    publisher = "Nature Publishing Group",
    doi = "10.1038/bmt.2016.129",
    keywords = "alemtuzumab;  bendamustine;  brentuximab vedotin;  chlorambucil;  fludarabine;  melphalan;  procarbazine;  steroid;  thiotepa;  treosulfan;  valganciclovir;  vincristine;  antibody conjugate;  brentuximab vedotin;  steroid, adolescent;  adult;  allogeneic stem cell transplantation;  Article;  cancer recurrence;  cancer survival;  chronic graft versus host disease;  clinical article;  clinical effectiveness;  consolidation chemotherapy;  controlled study;  cytomegalovirus infection;  diarrhea;  disease severity;  donor lymphocyte infusion;  drug megadose;  drug safety;  drug tolerability;  drug withdrawal;  female;  fever;  follow up;  Hodgkin disease;  human;  immunosuppressive treatment;  low drug dose;  male;  multicenter study (topic);  multiple cycle treatment;  neutropenia;  peripheral neuropathy;  priority journal;  progression free survival;  thrombocytopenia;  treatment duration;  treatment response;  virus reactivation;  young adult;  clinical trial;  complication;  evaluation study;  graft versus host reaction;  hematopoietic stem cell transplantation;  Hodgkin disease;  lymphocyte transfusion;  mortality;  multicenter study;  multimodality cancer therapy;  procedures;  survival analysis;  treatment outcome, Adolescent;  Adult;  Combined Modality Therapy;  Female;  Graft vs Host Disease;  Hematopoietic Stem Cell Transplantation;  Hodgkin Disease;  Humans;  Immunoconjugates;  Lymphocyte Transfusion;  Male;  Steroids;  Survival Analysis;  Treatment Outcome;  Young Adult",
    abstract = "In our study, we evaluated the safety and efficacy of Brentuximab vedotin (BV) with or without the addition of donor lymphocyte infusion (DLI) after allogeneic stem cell transplantation (allo-SCT) in 16 patients with advanced Hodgkin lymphoma (HL). Thirteen patients with relapsed HL after allo-SCT received BV as treatment for active disease. Three patients without progression of HL after allo-SCT received BV as consolidation. Twelve patients had been previously exposed to BV for treatment of relapse after autologous-SCT. Ten out of 16 patients received BV in combination with DLI. Among the 13 patients treated for active disease, CR and PR was observed in 7 and 2 patients, respectively. With a median follow-up of 13 months, 13 out of 16 patients are alive, while 3 died because of disease progression. The median PFS was 6 months. DLI-associated GVHD occurred in seven patients. Five patients with GVHD required immunosuppression, and in all cases, GVHD resolved after a short course of low dose steroids, implying that an anti-GVHD modulating effect could be induced by the concurrent administration of BV. No serious adverse event was observed in any of the patients."
}